Tag: peripheral neurotoxicity

#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone)

byKathleen Lau

January 1, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants
Poor baseline lung function associated with increased risk of incident tuberculosis
Endothelial Activation and Stress Index as a predictor of mortality in patients with atrial fibrillation

No Result

View All Result